Top Page
Rainmed Medical Limited
(2297)
Rainmed Medical Limited (2297) vs. iShares MSCI Hong Kong ETF (EWH)
Rainmed Medical Limited Business Overview & Revenue Model
Rainmed Medical Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 39.82M | 73.22M | 83.60M | 81.20M | 6.10M |
| Gross Profit | 23.87M | 48.55M | 69.82M | 69.03M | 5.26M |
| EBITDA | -82.98M | -93.54M | -1.33B | -623.97M | -148.23M |
| Net Income | -113.50M | -115.83M | -1.35B | -633.64M | -145.24M |
Balance Sheet | |||||
| Total Assets | 463.06M | 573.31M | 690.33M | 640.19M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 205.55M | 335.28M | 578.96M | 559.14M | 30.59M |
| Total Debt | 25.58M | 20.00M | 28.98M | 16.68M | 23.55M |
| Total Liabilities | 53.15M | 53.30M | 71.69M | 1.41B | 291.46M |
| Stockholders Equity | 407.00M | 515.05M | 618.64M | -774.48M | -220.93M |
Cash Flow | |||||
| Free Cash Flow | -138.10M | -235.27M | -141.04M | -103.95M | -1.76M |
| Operating Cash Flow | -84.31M | -124.29M | -111.22M | -72.83M | 2.27M |
| Investing Cash Flow | 6.31M | 180.29M | -515.74M | -27.98M | 8.69M |
| Financing Cash Flow | 723.00K | -15.88M | 120.73M | 633.85M | 9.53M |
Rainmed Medical Limited Technical Analysis
Rainmed Medical Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | 2.34B | 50.17 | -1.28% | ― | 32.93% | 0.00% | |
59 Neutral | 8.42B | 49.70 | 3.23% | 0.43% | 35.01% | 483.73% | |
57 Neutral | 1.61B | -12.49 | -9.03% | ― | -30.60% | 28.61% | |
51 Neutral | 3.33B | 627.27 | -2.26% | ― | -4.38% | 0.00% | |
50 Neutral | 1.60B | -2.28 | -32.31% | ― | -8.56% | -14.84% | |
47 Neutral | HK$462.45M | ― | -23.53% | ― | -53.10% | 10.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Rainmed Medical Limited Corporate Events
Rainmed Medical Limited reported a significant decline in its financial performance for the first half of 2025, with revenue dropping by 61.3% and gross profit falling by 72.7% compared to the same period in 2024. The company attributed its losses primarily to ongoing expenses related to research and development, manufacturing, and commercialization efforts. Despite these challenges, the company has not declared any interim dividend for the period, indicating a cautious approach to financial management amid declining revenues.
The most recent analyst rating on (HK:2297) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Rainmed Medical Limited stock, see the HK:2297 Stock Forecast page.
Rainmed Medical Limited has announced that its board of directors will meet on August 28, 2025, to review and approve the company’s unaudited interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend and address other business matters, which could impact the company’s financial positioning and stakeholder interests.
Rainmed Medical Limited announced significant changes in its executive leadership, with the resignation of several key figures, including the Chief Executive Officer and Vice President, effective July 15, 2025. The company has appointed Mr. Zhu Zeke as an executive director and joint chief executive officer, and Ms. Duan Jing as an executive director, reflecting a strategic shift in its management structure. These changes are part of an internal management adjustment aimed at strengthening the company’s operations and aligning with its strategic goals.
Rainmed Medical Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the membership of the board committees, highlighting the roles and functions of each director. This update is significant for stakeholders as it outlines the leadership structure and governance framework of the company, potentially impacting its strategic direction and operational oversight.
Rainmed Medical Limited announced that the Stock Exchange of Hong Kong has confirmed Mr. Zhang Liang’s qualifications to serve as the company’s secretary under the relevant listing rules. The company plans to continue with the arrangement of having joint company secretaries to enhance compliance and operational efficiency, reflecting its commitment to maintaining robust governance structures.
Rainmed Medical Limited announced that all proposed resolutions at their Annual General Meeting on June 27, 2025, were passed unanimously by shareholders. This includes the adoption of financial statements, re-election of directors, re-appointment of the auditor, and granting of mandates to the board for share allotment and repurchase, indicating strong shareholder support and stability in the company’s governance.
Rainmed Medical Limited announced the completion of a subscription agreement, resulting in the issuance of 233,559,800 new shares, which represents approximately 16.67% of the company’s enlarged share capital. This transaction has positioned the subscriber as a substantial shareholder and connected person under stock exchange rules, while the company has raised approximately HK$37.47 million in net proceeds to be used as previously disclosed.
Rainmed Medical Limited announced the resignation of Mr. Li Ho Man from his roles as an independent non-executive director and various committee positions, effective June 13, 2025, to focus on other business commitments. This resignation results in non-compliance with several Hong Kong Stock Exchange listing rules regarding the composition of the board and its committees. The company is actively seeking a suitable replacement to restore compliance within the stipulated three-month period.